89bio Inc (ETNB)
9.22
+0.36
(+4.06%)
USD |
NASDAQ |
May 03, 16:00
9.21
-0.01
(-0.11%)
After-Hours: 20:00
89bio Free Cash Flow: -129.19M for Dec. 31, 2023
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| December 31, 2023 | -129.19M |
| September 30, 2023 | -121.99M |
| June 30, 2023 | -106.44M |
| March 31, 2023 | -86.83M |
| December 31, 2022 | -81.10M |
| September 30, 2022 | -82.27M |
| June 30, 2022 | -80.92M |
| March 31, 2022 | -86.21M |
| December 31, 2021 | -76.84M |
| Date | Value |
|---|---|
| September 30, 2021 | -62.61M |
| June 30, 2021 | -62.10M |
| March 31, 2021 | -53.54M |
| December 31, 2020 | -46.37M |
| September 30, 2020 | -43.58M |
| June 30, 2020 | -36.83M |
| March 31, 2020 | -29.24M |
| December 31, 2019 | -25.60M |
Free Cash Flow Range, Past 5 Years
-129.19M
Minimum
Dec 2023
-25.60M
Maximum
Dec 2019
-71.27M
Average
-76.84M
Median
Dec 2021
Free Cash Flow Benchmarks
| Madrigal Pharmaceuticals Inc | -325.71M |
| Akero Therapeutics Inc | -145.37M |
| Viking Therapeutics Inc | -54.87M |
| Galectin Therapeutics Inc | -32.96M |
| Terns Pharmaceuticals Inc | -67.44M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -34.29M |
| Cash from Investing (Quarterly) | -63.64M |
| Cash from Financing (Quarterly) | 162.17M |
| Free Cash Flow Per Share (Quarterly) | -0.4244 |
| Free Cash Flow Yield | -19.70% |